The risk of cardiovascular complications in inflammatory bowel disease

Czubkowski, Piotr; Osiecki, Marcin; Szymańska, Edyta; Kierkuś, Jarosław

doi:10.1007/s10238-020-00639-y

Cited by 28 publications

(22 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Crohn’s disease and ulcerative colitis (UC) are two clinical manifestations of IBD characterized by chronic recurrent intestinal inflammation. Although the etiology of IBD remains largely unknown, it involves complex interactions between genetic, environmental or microbial factors and immune response ( Czubkowski et al, 2020 ). The common feature of IBD immune response is that mast cells, monocytes, macrophages and neutrophils invade the colonic epithelial layer, and then amplify the inflammatory process.…”

Section: Role Of Sphingosine Kinase 1 In Inflammatory Immune Related-diseasesmentioning

confidence: 99%

Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases

Hong

Deng

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Sphingosine kinase 1(SphK1) a key enzyme that catalyzes the conversion of sphingosine (Sph) to sphingosine 1-phosphate (S1P), so as to maintain the dynamic balance of sphingolipid-rheostat in cells and participate in cell growth and death, proliferation and migration, vasoconstriction and remodeling, inflammation and metabolism. The normal expression of SphK1 maintains the balance of physiological and pathological states, which is reflected in the regulation of inflammatory factor secretion, immune response in traditional immune cells and non-traditional immune cells, and complex signal transduction. However, abnormal SphK1 expression and activity are found in various inflammatory and immune related-diseases, such as hypertension, atherosclerosis, Alzheimer’s disease, inflammatory bowel disease and rheumatoid arthritis. In view of the therapeutic potential of regulating SphK1 and its signal, the current research is aimed at SphK1 inhibitors, such as SphK1 selective inhibitors and dual SphK1/2 inhibitor, and other compounds with inhibitory potency. This review explores the regulatory role of over-expressed SphK1 in inflammatory and immune related-diseases, and investigate the latest progress of SphK1 inhibitors and the improvement of disease or pathological state.

show abstract

Section: Role Of Sphingosine Kinase 1 In Inflammatory Immune Related-diseasesmentioning

confidence: 99%

Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases

Hong

Deng

2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…A potential link between CVD and gastrointestinal disorders [78][79][80][81] is in line with the lack of effectiveness of ColonVita on CGS in people with CGS-CVD comorbidity than in people without CGS-CVD comorbidity. It is known that myocardial ischemia and infarction can induce intestinal angina-related diarrhea, nausea, and vomiting [82,83].…”

Section: Discussionmentioning

confidence: 99%

The Relieving Effects of a Polyherb-Based Dietary Supplement ColonVita on Gastrointestinal Quality of Life Index (GIQLI) in Older Adults with Chronic Gastrointestinal Symptoms Are Influenced by Age and Cardiovascular Disease: A 12-Week Randomized Placebo-Controlled Trial

Xing

Zhang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Chronic gastrointestinal symptoms (CGS) negatively affect the quality of life in about 15–30% of the population without effective drugs. Recent studies suggest that dietary supplement may improve CGS, but inconsistent results exist. The goal of this study is to evaluate the effect of a polyherbal-based supplement ColonVita on the gastrointestinal quality of life index (GIQLI) in 100 old adults with CGS (63.1 ± 9.6 years) who were randomly assigned to daily ColonVita or placebo tablets (n = 50/group) for 12 weeks in a double-blind, randomized controlled trial design. No significant fibrdifferences were found between ColonVita and placebo in the baseline total GIQLI score (101.12 ± 16.87 vs. 101.80 ± 16.48) ( P > 0.05 ) or postintervention total GIQLI score (114.78 ± 9.62 vs. 111.74 ± 13.01) ( P > 0.05 ). However, ColonVita significantly improved 16 scores of the 19 core GI symptoms compared with 10 items improved by placebo. The ColonVita group significantly improved the remission rate of 5 core GI symptoms compared to placebo and significantly improved the total GIQLI scores (118.09 ± 7.88 vs. 109.50 ± 16.71) ( P < 0.05 ) and core GI symptom scores (64.61 ± 3.99 vs. 60.00 ± 8.65) ( P < 0.05 ) in people ≥60 years of age (n = 49) but not in those under 60 y (n = 51). ColonVita significantly improved the total GIQLI scores and core GI symptom scores in people without cardiovascular diseases (CVD) (n = 56) (116.74 ± 9.38 vs. 110.10 ± 14.28) ( P < 0.05 ) and (63.11 ± 4.53 vs. 59.93 ± 8.03) ( P = 0.07 ), respectively, but not in those with CVD (n = 44). Thus, ColonVita was beneficial for old adults with CGS, especially those ≥60 years of age and without CVD. Because a heterogenous pathogenesis of CGS-like irritable bowel syndrome (IBS) and inflammatory bowel disease (ISD) is differentially associated with CVD, different comorbidities may have influenced the outcomes of different trials that should be controlled in further studies.

show abstract

“…Атеросклероз в настоящее время рассматривается как хроническая воспалительная реакция артериальной стенки, в которую вовлечены cосудистый эндотелий, клетки крови, биологически активные вещества. В атерогенезе участвуют механизмы врожденного и адаптивного иммунитета [6].…”

Section: патофизиология взаимосвязи взк и атеросклерозаunclassified

“…Также он отвечает за свертываемость крови, выполняет барьерную функцию. Дисфункция эндотелия -это состояние, при котором нарушается баланс синтеза эндотелиальных факторов [6]. К структурным и функциональным изменениям эндотелия может приводить хроническое воспаление.…”

Section: патофизиология взаимосвязи взк и атеросклерозаunclassified

“…Ни один биохимический маркер сам по себе не является «золотым стандартом» определения активности ВЗК и сердечно-сосудистого риска (ССР). Известно, что долгосрочное повышение уровня ИЛ-6 и С-реактивного белка (СРБ) связано с возникновени-ем ССЗ [6,35]. В метаанализе 22 проспективных когортных исследований пациенты с высоким уровнем СРБ имели в 1,3 раза повышенный риск ИБС (ОР 1,33, 95% ДИ 1,22-1,44) по сравнению с общей популяцией после поправки на традиционные факторы ССР [7].…”

Section: использование визуализирующих и лабораторных методов для ран...unclassified

See 1 more Smart Citation

Аtherosclerosis and cardiovascular risk in patients with inflammatory bowel disease

Mironova

Isaikina

Khasieva

2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) can cause early atherosclerosis. There is a correlation between inflammatory activity in IBD and cardiovascular events. Chronic inflammation can lead to endothelial dysfunction. This review discusses the possibilities of the mechanisms underlying the relationship between IBD and atherosclerosis, the role of innate and humoral immunity, intestinal microbiota, biomarkers (C-reactive protein, homocysteine, etc.), as well as the possibility of early instrumental diagnosis of subclinical manifestations of atherosclerosis in patients with IBD by measuring carotid intimamedia thickness and aortic pulse wave velocity. The need for active prevention of cardiovascular diseases in this group of patients is emphasized, including through the control of inflammation activity, as well as the inclusion of IBD in one of the risk factors for cardiovascular diseases.

show abstract

The risk of cardiovascular complications in inflammatory bowel disease

Cited by 28 publications

References 72 publications

Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases

Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases

The Relieving Effects of a Polyherb-Based Dietary Supplement ColonVita on Gastrointestinal Quality of Life Index (GIQLI) in Older Adults with Chronic Gastrointestinal Symptoms Are Influenced by Age and Cardiovascular Disease: A 12-Week Randomized Placebo-Controlled Trial

Аtherosclerosis and cardiovascular risk in patients with inflammatory bowel disease

Contact Info

Product

Resources

About